MedTrace Logo

Adherence to Topical Hydrocortisone 17-butyrate 0.1% (Locoid®) Using Different Vehicles in Adults With Atopic Dermatitis

NCT00693693 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2018-09-10

Study results available
· View outcomes & findings →

Summary

The purpose of this research study is to better understand adherence to Locoid when people use it to treat atopic dermatitis.

Conditions

Interventions

DRUG

hydrocortisone 17-butyrate 0.1% Cream preparation

Apply medication twice a day to affected areas of atopic dermatitis

DRUG

hydrocortisone 17-butyrate 0.1% Ointment preparation

Apply medication twice a day to affected areas of atopic dermatitis

DRUG

hydrocortisone 17-butyrate 0.1% Lipocream preparation

Apply medication twice a day to affected areas of atopic dermatitis

Sponsors & Collaborators

  • Wake Forest University

    lead OTHER

Principal Investigators

  • Steve Feldman, MD, PhD · Wake Forest University Health Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2008-09-30
Completion
2008-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00693693 on ClinicalTrials.gov